fda
Market Access/ News/ News/ News/ R&D
US panel backs Omicron-targeting vaccines for booster campaigns
Phil Taylor
BioNTech, coronavirus, COVID-19, COVID-19 vaccine, fda, GlaxoSmithKline, Moderna, Novavax, Omicron, Pfizer, regulatory, variant
0 Comment
Market Access/ Views & Analysis/ Views and analysis
How the US’s pending PIE Act will improve patient access to medication
Jessica Hagen
AMCP, fda, Jennifer Mathieu, patient access
0 Comment
Sarepta shares yo-yo as FDA places hold on Duchenne trial
Phil Taylor
Duchenne muscular dystrophy, Exondys 51, fda, rare disease, regulatory, safety, Sarepta, vesleteplirsen
0 Comment
FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis
Phil Taylor
Acadia Pharmaceuticals, Alzheimer's disease, fda, Nuplazid, psychosis
0 Comment
Market Access/ Views & Analysis/ Views and analysis
Six months after authorization, what do we know about Paxlovid?
mike.hammerton@pharmaphorum.com
COVID-19, fda, Paxlovid, Pfizer
0 Comment
Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials
Ben Hargreaves
biologic medicines, China, fda, Lilly
0 Comment
Second unanimous FDA adcomm vote boosts bluebird bio
Phil Taylor
beta thalassaemia, bluebird bio, fda, gene therapy, rare disease, regulatory
0 Comment